Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2008
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy.Blood advances · 2024Article
- Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances.International journal of molecular sciences · 2023Review
- Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma.Cancer medicine · 2023Article
- MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation.BMC cancer · 2023Article
- Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma.Frontiers in oncology · 2023Article
- Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.Current oncology (Toronto, Ont.) · 2017Article
- Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.Blood and lymphatic cancer : targets and therapy · 2017Article
- Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2015Article
- Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!Bone marrow transplantation · 2014Review
- Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.ISRN oncology · 2014Review
- Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant.Haematologica · 2013Review
- Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up.Deutsches Arzteblatt international · 2013Article
- Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012Article
- Role of hematopoietic stem cell transplantation in relapsed/refractory hodgkin lymphoma.Mediterranean journal of hematology and infectious diseases · 2012Article
- Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.Current opinion in oncology · 2011Review
- The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma.Journal of the National Comprehensive Cancer Network : JNCCN · 2011Review
- Allogeneic haematopoietic stem cell transplantation as a salvage strategy for relapsed or refractory nasal NK/T-cell lymphoma.Medical oncology (Northwood, London, England) · 2011Article
- The role of autologous transplantation in Hodgkin lymphoma.Current hematologic malignancy reports · 2011Review
- Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?Bone marrow transplantation · 2009Review
- Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
We determined treatment-related mortality, progression-free survival (PFS), and overall survival (OS) after a second autologous HCT (HCT2) for patients with lymphoma relapse after a prior HCT (HCT1). Outcomes for patients with either Hodgkin lymphoma (HL, n = 21) or non-Hodgkin lymphoma (NHL, n = 19) receiving HCT2 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) were analyzed. The median age at HCT2 was 38 years (range: 16-61) and 22 (58%) patients had a Karnofsky performance score <90. HCT2 was performed >1 year after HCT1 in 82%. The probability of treatment-related mortality at day 100 was 11% (95% confidence interval [CI], 3%-22%). The 1-, 3-, and 5-year probabilities of PFS were 50% (95% CI, 34%-66%), 36% (95% CI, 21%-52%), and 30% (95% CI, 16%-46%), respectively. Corresponding probabilities of survival were 65% (95% CI, 50%-79%), 36% (95% CI, 22%-52%), and 30% (95% CI, 17%-46%), respectively. At a median follow-up of 72 months (range: 12-124 months) after HCT2, 29 patients (73%) have died, 18 (62%) secondary to relapsed lymphoma. The outcomes of patients with HL and NHL were similar. In summary, this series represents the largest reported group of patients with relapsed lymphomas undergoing SCT2 following failed SCT1, and with long-term follow-up. Our series suggests that SCT2 is feasible in patients relapsing after prior HCT1, with a lower treatment-related mortality than that reported for allogeneic transplant in this setting. HCT2 should be considered for patients with relapsed HL or NHL after HCT1 without alternative allogeneic stem cell transplant options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.